These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 21684151)
1. Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062. O'Brien ME; Konopa K; Lorigan P; Bosquee L; Marshall E; Bustin F; Margerit S; Fink C; Stigt JA; Dingemans AM; Hasan B; Van Meerbeeck J; Baas P Eur J Cancer; 2011 Oct; 47(15):2322-30. PubMed ID: 21684151 [TBL] [Abstract][Full Text] [Related]
2. A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer. Quoix E; Breton JL; Gervais R; Wilson J; Schramel F; Cardenal F; Ross G; Preston A; Lymboura M; Mattson K Lung Cancer; 2005 Aug; 49(2):253-61. PubMed ID: 16022920 [TBL] [Abstract][Full Text] [Related]
3. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. Eckardt JR; von Pawel J; Papai Z; Tomova A; Tzekova V; Crofts TE; Brannon S; Wissel P; Ross G J Clin Oncol; 2006 May; 24(13):2044-51. PubMed ID: 16648504 [TBL] [Abstract][Full Text] [Related]
4. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group. Jett JR; Hatfield AK; Hillman S; Bauman MD; Mailliard JA; Kugler JW; Morton RF; Marks RS; Levitt R Cancer; 2003 May; 97(10):2498-503. PubMed ID: 12733149 [TBL] [Abstract][Full Text] [Related]
5. Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group. Kelly K; Lovato L; Bunn PA; Livingston RB; Zangmeister J; Taylor SA; Roychowdhury D; Crowley JJ; Gandara DR; Clin Cancer Res; 2001 Aug; 7(8):2325-9. PubMed ID: 11489808 [TBL] [Abstract][Full Text] [Related]
6. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Ardizzoni A; Manegold C; Debruyne C; Gaafar R; Buchholz E; Smit EF; Lianes P; ten Velde G; Bosquee L; Legrand C; Neumaier C; King K; Clin Cancer Res; 2003 Jan; 9(1):143-50. PubMed ID: 12538462 [TBL] [Abstract][Full Text] [Related]
7. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study. Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW; J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930 [TBL] [Abstract][Full Text] [Related]
8. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. Ettinger DS; Jotte R; Lorigan P; Gupta V; Garbo L; Alemany C; Conkling P; Spigel DR; Dudek AZ; Shah C; Salgia R; McNally R; Renschler MF; Oliver JW J Clin Oncol; 2010 May; 28(15):2598-603. PubMed ID: 20385980 [TBL] [Abstract][Full Text] [Related]
9. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer. Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753 [TBL] [Abstract][Full Text] [Related]
10. Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer. Hirose T; Nakashima M; Shirai T; Kusumoto S; Sugiyama T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M Lung Cancer; 2011 Sep; 73(3):345-50. PubMed ID: 21277039 [TBL] [Abstract][Full Text] [Related]
11. A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer. Ikeda T; Fukuda M; Nakamura Y; Kinoshita A; Senju H; Nakano H; Kitazaki T; Ogawara D; Taniguchi H; Motoshima K; Yamaguchi H; Nakatomi K; Shimada M; Nagashima S; Tsukamoto K; Kohno S; Cancer Chemother Pharmacol; 2014 Sep; 74(3):497-502. PubMed ID: 25034978 [TBL] [Abstract][Full Text] [Related]
12. Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trial. Sorensen M; Lassen U; Palshof T; Jensen BB; Johansen J; Jensen PB; Langer SW Lung Cancer; 2008 May; 60(2):252-8. PubMed ID: 18036701 [TBL] [Abstract][Full Text] [Related]
13. Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer. Hong J; Jung M; Kim YJ; Sym SJ; Kyung SY; Park J; Lee SP; Park JW; Cho EK; Jeong SH; Shin DB; Lee JH Cancer Chemother Pharmacol; 2012 Jan; 69(1):215-20. PubMed ID: 21691745 [TBL] [Abstract][Full Text] [Related]
14. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401. Nogami N; Hotta K; Kuyama S; Kiura K; Takigawa N; Chikamori K; Shibayama T; Kishino D; Hosokawa S; Tamaoki A; Harita S; Tabata M; Ueoka H; Shinkai T; Tanimoto M Lung Cancer; 2011 Oct; 74(1):80-4. PubMed ID: 21334093 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma. A phase II study of the Southwest Oncology Group. Figlin RA; Crowley JJ; Jacobs EL; Muirhead M; Goodwin JW; Rinehart JJ; Livingston RB Cancer; 1996 Sep; 78(5):998-1003. PubMed ID: 8780537 [TBL] [Abstract][Full Text] [Related]
16. A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer. Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Shimizu K; Imai H; Utsugi M; Iwasaki Y; Iijima H; Tsurumaki H; Yoshii A; Fueki N; Hisada T; Ishizuka T; Saito R; Mori M Lung Cancer; 2010 Jul; 69(1):99-104. PubMed ID: 19853960 [TBL] [Abstract][Full Text] [Related]
17. [Comparing cisplatin plus etoposide with combination of mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer patients]. Cok G; Göksel T; Soyer S; Atil H; Güzelant A; Aysan T Tuberk Toraks; 2006; 54(2):161-7. PubMed ID: 16924573 [TBL] [Abstract][Full Text] [Related]
18. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale). Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G; Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419 [TBL] [Abstract][Full Text] [Related]
19. Phase II study of uracil-tegafur plus cisplatin in patients with previously untreated advanced non-small cell lung cancer. Takayama K; Kawasaki M; Ninomiya K; Motohiro A; Fujita M; Watanabe K; Kajiki A; Iwami F; Miyazaki N; Izumi M; Hara N; Nakanishi Y; Respirology; 2008 Jan; 13(1):103-7. PubMed ID: 18197918 [TBL] [Abstract][Full Text] [Related]
20. Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma. Tas F; Derin D; Guney N; Camlica H; Aydiner A; Topuz E Lung Cancer; 2007 Jul; 57(1):79-83. PubMed ID: 17383768 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]